Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 6, 2000, Pages 651-668

  Laine, L ^a   Ahnen, D ^b   McClain, C ^c   Solcia, E ^d   Walsh, J H ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FAT; GASTRIN; LANSOPRAZOLE; MINERAL; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; VITAMIN;

ATROPHIC GASTRITIS; BACTERIAL OVERGROWTH; CARCINOID; COLON CANCER; ENTERITIS; ENTEROCHROMAFFIN CELL; GASTRIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE METAPLASIA; LIPID ABSORPTION; LONG TERM CARE; MALABSORPTION; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ANTI-ULCER AGENTS; CARCINOID TUMOR; GASTRIC ACID; HELICOBACTER INFECTIONS; HUMANS; MALABSORPTION SYNDROMES; PROTON PUMPS; RISK FACTORS; STOMACH DISEASES; STOMACH NEOPLASMS; STOMACH ULCER;

EID: 0034038649     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00768.x     Document Type: Review

References (141)

1. 2-receptor antagonist on food-stimulated acid secretion, serum gastrin, and gastric emptying in patients with duodenal ulcers: comparison with an anticholinergic drug. J Clin Invest 1975; 55: 536-42.
2. 2 Allen JM, Adrian TE, Webster J, Howe A, Bloom SR. Effect of single dose of omeprazole on the gastrointestinal peptide response to food. Hepatogastroenterology 1984; 31: 44-6.
3. 3 Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1: 239-51.
4. 4 Creutzfeldt W, Lamberts R. Is hypergastrinaemia dangerous to man? Scand J Gastroenterol 1991; 26(Suppl. 180): 179-91.
5. 5 Larsson H, Håkanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E. Omeprazole: Its influence on gastric acid secretion, gastrin, and ECL cells. Toxicol Pathol 1988; 16: 267-72.
6. 6 Ryberg B, Mattsson H, Sundler F, et al. Effects of inhibition of gastric acid secretion in rats on plasma gastrin levels and density of enterochromaffinlike cells in the oxyntic mucosa. In: Krailer J, Marks GS, eds. Proceedings from 6th International Symposium on Gastrointestinal Hormones. Vancouver: National Research Council of Canada, 1986: 34-5.
7. 7 Larsson H, Carlsson E, Mattsson H, et al. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391-9.
8. 8 Ryberg B, Mattsson H, Carlsson E. Effects of omeprazole and ranitidine on gastric acid secretion, blood gastrin levels and [3H]-thymidine incorporation in the oxyntic mucosa from dogs and rats. Digestion 1988; 39: 91-9.
9. 9 Carney JA, Go VLW, Fairbanks VF, Moore SB, Alport EC, Nora FE. The syndrome of gastric argyrophil carcinoid tumours and nonantral gastric atrophy. Ann Intern Med 1983; 99: 761-6.
10. 10 Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anaemia. Gastroenterology 1985; 88: 638-48.
11. 11 Borch K, Renvall H, Kullman E, Wilander E. Gastric carcinoid associated with the syndrome of hypergastrinemic atrophic gastritis. Am J Surg Pathol 1987; 11: 435-44.
12. 12 Solcia E, Capella C, Vassallo G. Endocrine cells of the stomach and pancreas in states of gastric hypersecretion. Rendic R Gastroenterol 1970; 2: 147-58.
13. 13 Bordi C, Cocconi G, Togni R, Vezzadini P, Missale G. Gastric endocrine cell proliferation: association with Zollinger-Ellison syndrome. Arch Pathol 1974; 98: 274-8.
14. 14 Bardram L, Thomsen P, Stadil F. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome. Digestion 1986; 35(Suppl. 1): 116-22.
15. 15 Solcia E, Capella C, Fiocca R, Rindi G, Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 503-13.
16. 16 Johnson LR, Guthrie PD. Mucosal DNA synthesis: a short term index of the trophic action of gastrin. Gastroenterology 1974; 67: 453-9.
17. 17 Solomon TE. Trophic effects of pentagastrin on gastrointestinal tract on fed and fasted rats. Gastroenterology 1986; 91: 108-16.
18. 18 Ruddell WSJ, Axon ATF, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet 1980; 1: 672-4.
19. 19 Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol 1985; 20(Suppl. 111): 7-16.
20. 20 Brand SJ, Schmidt WE, et al. Gastrointestinal hormones. In: Alpers DH, Powell DW, Owyang C, Silverstein FE, eds. Textbook of Gastroenterology. Philadelphia: J.B. Lippincott, 1995: 25-71.
21. 21 Walsh JH. Role of gastrin as a trophic hormone. Digestion 1990; 47(Suppl. 1): 11-6.
22. 22 Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med 1988; 319: 1707-15.
23. 23 Håkanson R, Sundler F. Proposed mechanism of induction of gastric carcinoids: the gastrin hypothesis. Eur J Clin Invest 1990; 20(Suppl. 1): S65-71.
24. 24 DelValle J, et al. Gastric secretion. In: Yamada T, Alpers DH, Powell DW, Owyang C, Silverstein FE, eds. Textbook of Gastroenterology. Philadelphia: J.B. Lippincott, 1995; 295-326.
25. 25 Mattsson H, Havu N, Bräutigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterology 1991; 100: 311-9.
26. 26 Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35(Suppl.): 42-55.
27. 27 Havu N, Mattsson H, Ekman L, Carlsson E. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 1990; 45: 189-95.
28. 28 Lee H, Håkanson R, Karlsson A, Mattsson H, Sundler F. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in rat stomach. Digestion 1992; 51: 125-32.
29. 29 Ryberg B, Axelson J, Håkanson R, Sundler F, Mattsson H. Trophic effects of continuous infusion of [Leu 15]-gastrin-17 in the rat. Gastroenterology 1990; 98: 33-8.
30. 30 Larsson H, Carlsson E, Håkanson R, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1988; 95: 1477-86.
31. 31 Delwaide J, Latour P, Gast P, Louis E, Belaiche J. Effects of proglumide and enprostil on omeprazole-induced fundic endocrine cell hyperplasia in rats. Gastroenterol Clin Biol 1993; 17: 792-6.
32. 32 Freston JW. Clinical significance of hypergastrinemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51(Suppl. 1): 102-14.
33. 33 Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol 1985; 20(Suppl. 108): 53-69.
34. 34 Axelson J, Håkanson R, Rosengren E, Sundler F. Hypergastrinaemia induced by acid blockade evokes enterochromaffin-like (ECL) cell hyperplasia in chicken, hamster and guinea-pig stomach. Cell Tissue Res 1988; 254: 511-6.
35. 35 Håkanson R, Larsson L-I, Liedberg G, Oscarson J, Sundler F, Vang J. Effects of antrectomy or porta-caval shunting on the histamine-storing endocrine-like cells in oxyntic mucosa of rat stomach. A fluorescence histochemical, electron microscopic and chemical study. J Physiol 1976; 259: 785-800.
36. 36 Simonsson M, Eriksson S, Håkanson R, et al. Endocrine cells in the human oxyntic mucosa. A histochemical study. Scand J Gastroenterol 1988; 23: 1089-99.
37. 37 Delle Fave G, Helander H, Holt S, et al. Acid suppression and gastric mucosal cell biology. Dig Dis Sci 1995; 40(Feb Suppl.): 121S-131S.
38. 38 Solcia E, Fiocca R, Villani L, et al. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterology 1991; 26(Suppl. 180): 146-59.
39. 39 Solcia E, Fiocca R, Villani L, Luinetti O, Capella C. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995; 19(Suppl. 1): S1-7.
40. 40 Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994-1006.
41. 41 Solcia E, Villani L, Luinetti O, Fiocca R. Proton pump inhibitors, enterochromaffin-like cell growth and Helicobacter pylori gastritis. Aliment Pharmacol Ther 1993; 7(Suppl. 1): 25-8.
42. 42 Solcia E, Rindi G, Fiocca R, et al. Endocrine proliferations and carcinoids in hypergastrinemia. In: Walsh JH, ed. Gastrin. New York: Raven, 1993: 361-71.
43. 43 Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anaemia after antrectomy. Gastroenterology 1992; 102: 1409-18.
44. 44 Fass R, Rosen HR, Walsh JH. Zollinger-Ellison syndrome: diagnosis and management. Hosp Pract 1995; 30: 73-80.
45. 45 Eissele R, Brunner G, Simon B, Solcia Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17.
46. 46 Eissele R, Brunner G, Fischer B, Fuchs W, Koop H, Arnold R. Evaluation of enterochromaffin-like (ECL)-cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole. Gastroenterology 1993; 104: A74 (Abstract).
47. 47 Brunner G, Harke U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994; 8(Suppl. 1): 59-64.
48. 48 Solcia E, Rindi G, Havu N, Elm G. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol 1989; 24(Suppl. 166): 129-37.
49. 49 Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
50. 2-blocker-resistant esophagitis. Dig Dis Sci 1991; 36: 552-7.
51. 51 Lundell L, Backman L, Ekström P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248-56.
52. 52 Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-8.
53. 53 Solcia E, Fiocca R, Havu N, Dalväg A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51(Suppl. 1): 82-92.
54. 54 Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
55. 55 Hallerbäck B, Unge P, Carling L, et al. The Scandinavian Clinics for United Research Group. Omeprazole or ranitidine in long-term treatment of reflux esophagitis? Gastroenterology 1994; 107: 1305-11.
56. 56 Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
57. 57 Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102: 720-7.
58. 58 Fiocca R, Villani L, Luinetti O, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol 1992; 420: 489-98.
59. 59 Tytgat GNJ, Noach LA, Rauws EAJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin North Am 1993; 22: 127-39.
60. 60 NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
61. 61 Parsonnet J. Helicobacter pylori in the stomach - a paradox unmasked. N Engl J Med 1996; 335: 278-80.
62. 62 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes and Helicobacter Pylori. Lyon: International Agency for Research on Cancer. 1994.
63. 63 Dixon MF, Genta RM, Yardley JH, Correa P, and the Participants in the International Workshop on the Histopathology of Gastritis, Houston 1994. Classification and Grading of Gastritis. The Updated Sydney System. Am J Surg Pathol 1996; 20: 1161-81.
64. 64 Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol 1988; 83: 504-9.
65. 65 Rubin CF. Are there three types of Helicobacter pylori gastritis? Gastroenterology 1997; 112: 2108-10.
66. 66 Morson BC. Intestinal metaplasia of the gastric mucosa. Br J Cancer 1955; 9: 365-76.
67. 67 ebbel R. Chronic gastritis: its relation to gastric and duodenal ulcer and to gastric carcinoma. Am J Pathol 1943; 19: 43-71.
68. 68 Genta RM, Robason GO, Graham DY. Inflammatory responses and intensity of Helicobacter pylori infection in patients with duodenal and gastric ulcer: histopathologic analysis with a new stain. Acta Histochem Cytochem 1995; 28: 67-72.
69. 69 Stemmermann GN. Intestinal metaplasia of the stomach. Cancer 1994; 74: 556-64.
70. 70 MacDonald WC, Rubin CE. Gastric biopsy - a critical evaluation. Gastroenterology 1967; 53: 143-70.
71. 71 Hansson L-E, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335: 242-9.
72. 72 Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35: 173-7.
73. 73 Fiocca R, Luinetti O, Villani L, et al. High incidence of Helicobacter pylori colonization in early gastric cancer and the possible relationship to carcinogenesis. Eur J Gastroenterol Hepatol 1993; 5(Suppl. 2): S52-8.
74. 74 Stolte M, Bethke B, Blum AL, Suser E, Stadelmann O. Antacid treatment has a deleterious effect on the severity and activity of gastritis of the corpus mucosa. It Med Sci 1992; 161 (Suppl. 10): 6.
75. 75 Solcia E, Villani L, Fiocca R, et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994; 29(Suppl. 201): 28-34.
76. 76 Bank S, Blumstein M, Greenberg R, Austin-Brigante L. Is intermittent or spaced omeprazole dosing in the maintenance treatment of erosive esophagitis a therapeutic option? Results after 2-8 years of continuous therapy. Am J Gastroenterol 1996; 91: 1882.
77. 77 Goh KL, Boonyapisit S, Lai K-H, Chang R, Kang JY, Lam SK. Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: a randomized double-blind, placebo-controlled study. J Gastroenterol Hepatol 1995; 10: 92-7.
78. 78 Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50: 4737-40.
79. 79 Lundell L, Havu N, Andersson A, et al. Gastritis development and acid suppression therapy revisited. Results of a randomized clinical study with long-term follow-up. Gastroenterology 1997; 112: A28(Abstract).
80. 80 Proton Pump Inhibitor Relieving for Cancer Risk Not Warranted. F-D-C Reports 1996: 58.
81. 81 Ware J, Corcoran GD, Day DW, et al. An investigation of possible risk factors associated with gastric cancer after benign ulcer operations. In: Bartsch H, O'Neill IK, Schulte-Hermann R, eds. Relevance of N-Nitroso Compounds to Human Cancer: Exposures and Mechanisms. Lyons: IARC Science Publishers, 1987: 531-3.
82. 82 Lechago J, Correa P. Prolonged achlorhydria and gastric neoplasia: Is there a causal relationship? Gastroenterology 1993; 104: 1554-7.
83. 83 Ruddell WSJ, Bone ES, Hill MJ, Blendis LM, Walters CL. Gastric-juice nitrite. A risk factor for cancer in the hypochlorhydric stomach? Lancet 1976; 2: 1037-9.
84. 84 Svendsen JH, Dahl C, Svendsen LB, Christiansen PM. Gastric cancer risk in achlorhydric patients: a long-term follow-up study. Scand J Gastroenterol 1986; 21: 16-20.
85. 85 Elsborg L, Mosbech J. Pernicious anaemia as a risk factor in gastric cancer. Acta Med Scand 1979; 206: 315-8.
86. 86 Schafer LW, Larson DE, Melton LJ III, Higgins JA, Zinsmeister AR. Risk of development of gastric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1985; 60: 444-8.
87. 87 Carter DC. Cancer after peptic ulcer surgery. Gut 1987; 28: 921-3.
88. 88 Caygill CPJ, Hill MJ, Kirkham JS, Northfield TC. Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1986; 1: 929-31.
89. 89 Smith JP, Wood JG, Solomon TE. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 1989; 34: 171-4.
90. 90 Seitz JF, Giovanni M, Gouvernet J, Gauthier AP. Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol 1991; 13: 541-5.
91. 91 Ciccotosto GD, McLeish A, Hardy KJ, Shulkes A. Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 1995; 109: 1142-53.
92. 92 Suzuki H, Matsumoto K, Terashima H. Serum levels of gastrin in patients with colorectal neoplasia. Dis Colon Rectum 1988; 31: 716-7.
93. 93 Yapp R, Modlin IM, Kumar R, Binder HJ, Dubrow R. Gastrin and colon cancer: evidence against an association. Dig Dis Sci 1992; 37: 481-4.
94. 94 Charnley RM, Thomas WM, Stanley J, Morris DL. Serum gastrin concentrations in colorectal cancer patients. Ann R Coll Surg Engl 1992; 74: 138-41.
95. 95 Kikendall JW, Glass AR, Sobin LH, Bowen PE. Serum gastrin is not higher in subjects with colonic neoplasia. Am J Gastroenterol 1992; 87: 1394-7.
96. 96 Penman ID, El-Omar E, Ardill JES, et al. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology 1994; 106: 1263-70.
97. 97 Johnson LR, Lichtenberger LM, Copeland EM, Dudrick SJ, Castro GA. Action of gastrin on gastrointestinal structure and function. Gastroenterology 1975; 68: 1184-92.
98. 98 Dembinski AB, Johnson LR. Growth of pancreas and gastrointestinal mucosa in antrectomized and gastrin-treated rats. Endocrinol 1979; 105: 769-73.
99. 99 Johnson LR, Guthrie PD. Proglumide inhibition of trophic action of pentagastrin. Am J Physiol 1984; 246: G62-6.
100. 100 Mak KM, Chang WWL. Pentagastrin stimulates epithelial cell proliferation in duodenal and colonic crypts in fasted rats. Gastroenterology 1976; 71: 1117-20.
101. 101 Håkanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F. Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul Pept 1986; 13: 225-33.
102. 102 Winsett OE, Townsend CM Jr, Glass EJ, Thompson JC. Gastrin stimulates growth of colon cancer. Surgery 1986; 99: 302-7.
103. 103 Graffner H, Singh G, Chaudry I, Milsom JW. Omeprazole-induced hypergastrinemia does not influence growth of colon carcinoma. Dig Dis Sci 1992; 37: 485-9.
104. 104 Hurwitz A, Sztern MI, Looney GA, Pinson DM, Bauer KD, Kimler BF. Effects of omeprazole on cell kinetics of carcinogen-induced colon tumours in rats. Cell Prolif 1995; 28: 525-31.
105. 105 Karlin DA, McBath M, Jones RD, Elwyn KE, Romsdahl MM. Hypergastrinemia and colorectal carcinogenesis in the rat. Cancer Lett 1985; 29: 73-8.
106. 106 Tatsuta M, Yamamura H, Ichii M, Taniguchi H. Effect of prolonged administration of gastrin on experimental carcinogenesis in rat colon induced by intrarectal instillation of N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Res 1983; 43: 2258-60.
107. 107 Pinson DM, Havu N, Sztern MI, et al. Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology 1995; 108: 1068-74.
108. 108 Penman ID, El-Omar E, McGregor JR, Hillan KJ, O'Dwyer PJ, McColl KEL. Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats. Gut 1993; 34: 1559-65.
109. 109 D'Agostino L, Pignata S, Tritto G, et al. Hypergastrinemia in rats with azoxymethane-induced colon cancers. Int J Cancer 1995; 61: 223-6.
110. 110 Sobhani I, Lehy T, Laurent-Puig P, Cadiot G, Ruszniewski P, Mignon M. Chronic endogenous hypergastrinemia in humans: evidence for mitogenic effect on the colonic mucosa. Gastroenterology 1993; 105: 22-30.
111. 111 Biasco G, Brandi G, Renga M, Paganelli GM, Tomassetti P, Calabrese C. Is there a relationship between hypergastrinemia and colorectal cancer risk? Rectal cell proliferation in Zollinger-Ellison syndrome. Am J Gastroenterol 1995; 90: 1365-6.
112. 112 Talley NJ, Chute CG, Larson DE, Epstein R, Lydick EG, Melton LJ III Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. Ann Intern Med 1989; 111: 738-42.
113. 113 Brinton LA, Gridley G, Hrubec Z, Hoover R. Fraumeni JF Jr Cancer risk following pernicious anaemia. Br J Cancer 1989; 59: 810-3.
114. 114 Thiruvengadam R, Hench V, Melton J III, DiMagno EP. Cancer of the nongastric hollow organs of the gastrointestinal tract after gastric surgery. Arch Intern Med 1988; 148: 405-7.
115. 115 Siurala M, Lehtola J, Ihamäki T. Atrophic gastritis and its sequelae. Results of 19-23 years' follow-up examinations. Scand J Gastroenterol 1974; 9: 441-6.
116. 116 Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J 1984; 289: 717-9.
117. 117 Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 1994; 35: 455-60.
118. 118 Stockbrugger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment. Gut 1982; 23: 1048-54.
119. 119 Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35: 23-6.
120. 120 Howden CW, Hunt RH. The relationship between gastric secretion and infection. Gut 1987; 28: 96-107.
121. 121 Allan Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut 1967; 8: 574-81.
122. 122 Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54-9.
123. 123 Yeomans ND, Brimblecombe RW, Elder J, et al. Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 1995; 40: 81S-95S.
124. 124 Rowland JR. The toxicology of N-nitroso compounds. In: Hill MJ, ed. Nitrosamines - Toxicology and Microbiology. London: Ellis Horwood, 1988: pp. 117-41.
125. 125 Reed PI, Haines K, Smith PLR, House FR, Walters CL. Effect of cimetidine on gastric juice N-nitrosamine concentration. Lancet 1981; 2: 553-6.
126. 126 Giannella RA, Broitman SA, Zamcheck N. Salmonella enteritis. I. Role of reduced gastric secretion in pathogenesis. Dig Dis 1971; 16: 1000-6.
127. 127 Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med 1973; 78: 271-6.
128. 128 Dupont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in Shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis 1972; 125: 5-11.
129. 129 Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP, Hornick RB. Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis 1974; 129: 45-52.
130. 130 Nalin DR, Levine RJ, Levine MM, et al. Cholera, non-vibrio cholera, and stomach acid. Lancet 1978; 2: 856-9.
131. 131 Wingate DL. Acid reduction and recurrent enteritis. Lancet 1990; 335: 222.
132. 132 Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacteria gastroenteritis. How much of a risk? Epidemiol 1997; 8: 571-4.
133. 133 Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 1994; 106: 615-23.
134. 134 Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995; 14: 364-8.
135. 12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992; 14: 288-92.
136. 136 Allen RH, Seetharam B, Podell E, Alper DH. Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. J Clin Invest 1978; 61: 47-54.
137. 137 Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci 1980; 25: 188-91.
138. 12). Ann Intern Med 1994; 120: 211-5.
139. 139 Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992; 6: 399-406.
140. 140 Festen H, Klinkenberg-Knol E, Kuipers E, et al. Cobalamin absorption during omeprazole treatment: short and long-term studies. Gastroenterology 1993; 104: A77(Abstract).
141. 12 levels in patients with Zollinger-Ellison syndrome. Gastroenterology 1995; 108: A226(Abstract).